DR. SANCHARI SARKAR

Dr. SANJAY KUMAR DAULAT THAKUR, DR. AVANTIKA SRIVASTAVA, Dr.PAYEL KHATUA

Abstract

Objective: To compare Central Macular Thickness (CMT) in patients with Retinal Vein Occlusion (RVO) on receiving Intravitreal Ranibizumab (IVR) as per Monthly, Pro Re Nata (PRN) and Treat and Extend (T&E) Protocol. Method: 81 patients with RVO were enrolled in a prospective cohort study and divided in 1:1:1 ratio randomly, where group A received IVR monthly, group B and C received it as per PRN and T&E protocol respectively. CMT was measured preoperatively and on every subsequent follow up using Spectral Domain Optical Coherence Tomography for 9 months. Results: The mean decrease in CMT in Group A, Group B and Group C was 236.19 ± 34.94µm, 135.59 ± 22.83µm and 178.04 ± 34.73µm respectively. The mean decrease in CMT was significantly greater in Group A compared to Group B (p=0.000004); Group C compared to Group B (p=0.002) and Group A compared to Group C (p=0.02). Conclusion: Monthly protocol of IVR was found to be the most efficient regime for RVO.